Compare Wheaton Precious Metals Corp (WPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wheaton Precious Metals Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Wheaton Precious Metals Corp trades at $158 (market cap $70.35B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: Wheaton Precious Metals Corp pays a 0.5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| WPM | XBI | |
|---|---|---|
Market Cap | $70.35B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $165.72 | $169.55 |
52-Week Low | $94.37 | $93.43 |
Enterprise Value | $72.23B | — |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.19 versus $1.15 expected, and record revenue of $2.31 billion in 2025 underscore robust operational momentum. The company's royalty and streaming model continues to deliver high margins, with a net income margin of 64.66% in 2025.
The outlook remains positive, supported by an 80% analyst buy rating and a consensus price target of $161.75, though risks include exposure to commodity price volatility and significant capital expenditures projected for 2026. The stock's current valuation multiples, such as a P/E of 34.41, reflect premium pricing relative to historical norms.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
